JP7808042B2 - ギンセノシド組成物 - Google Patents
ギンセノシド組成物Info
- Publication number
- JP7808042B2 JP7808042B2 JP2022555990A JP2022555990A JP7808042B2 JP 7808042 B2 JP7808042 B2 JP 7808042B2 JP 2022555990 A JP2022555990 A JP 2022555990A JP 2022555990 A JP2022555990 A JP 2022555990A JP 7808042 B2 JP7808042 B2 JP 7808042B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- extract
- ginsenosides
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004121.6A GB202004121D0 (en) | 2020-03-20 | 2020-03-20 | Improved compositions |
| GB2004121.6 | 2020-03-20 | ||
| GB2005288.2 | 2020-04-09 | ||
| GBGB2005288.2A GB202005288D0 (en) | 2020-04-09 | 2020-04-09 | Improved compositions |
| PCT/EP2021/056803 WO2021185897A1 (en) | 2020-03-20 | 2021-03-17 | Ginsenoside compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518064A JP2023518064A (ja) | 2023-04-27 |
| JP2023518064A5 JP2023518064A5 (cg-RX-API-DMAC7.html) | 2024-03-29 |
| JP7808042B2 true JP7808042B2 (ja) | 2026-01-28 |
Family
ID=75108332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555990A Active JP7808042B2 (ja) | 2020-03-20 | 2021-03-17 | ギンセノシド組成物 |
| JP2022556000A Active JP7850670B2 (ja) | 2020-03-20 | 2021-03-17 | ギンセノシド組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556000A Active JP7850670B2 (ja) | 2020-03-20 | 2021-03-17 | ギンセノシド組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230124503A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4121061A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7808042B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115315264A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021238639B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112022015826A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3174699A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021185897A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230124503A1 (en) * | 2020-03-20 | 2023-04-20 | Givaudan Sa | Ginsenoside compositions |
| JP2023161983A (ja) * | 2022-04-26 | 2023-11-08 | 石川県公立大学法人 | サポニンを含む酪酸産生菌増殖能向上組成物、腸内常在菌増殖能向上組成物、乳酸菌増殖能向上組成物及びビフィズス菌増殖能向上組成物 |
| CN117224553B (zh) * | 2023-11-02 | 2025-08-12 | 浙江大学 | 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用 |
| CN117752706B (zh) * | 2023-12-20 | 2025-10-14 | 浙江天皇药业有限公司 | 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用 |
| WO2025261873A1 (en) | 2024-06-20 | 2025-12-26 | Givaudan Sa | Improvements in or relating to compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150306119A1 (en) | 2009-05-04 | 2015-10-29 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
| US20160339070A1 (en) | 2013-11-04 | 2016-11-24 | Wen Luan Wendy Hsiao | Use of herbal saponins to regulate gut microflora |
| CN109432304A (zh) | 2018-12-03 | 2019-03-08 | 杭州胡庆余堂药业有限公司 | 一种含铁皮石斛组合物在药物制备中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040202731A1 (en) * | 2003-04-08 | 2004-10-14 | Gow Robert T. | Rosmarinic acid composition |
| US20100278944A1 (en) * | 2009-05-04 | 2010-11-04 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
| KR102200012B1 (ko) * | 2013-04-02 | 2021-01-08 | (주)아모레퍼시픽 | 인삼열매 추출물을 포함하는 뇌 활성화 조성물 |
| BR112020000963A2 (pt) | 2017-07-18 | 2020-07-14 | Senescence Life Sciences Pte. Ltd. | composições e métodos para o tratamento e prevenção de declínio cognitivo e conservação da função neuronal |
| CN110613802A (zh) * | 2018-06-20 | 2019-12-27 | 珠海岐微生物科技有限公司 | 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途 |
| US20230124503A1 (en) | 2020-03-20 | 2023-04-20 | Givaudan Sa | Ginsenoside compositions |
-
2021
- 2021-03-17 US US17/905,849 patent/US20230124503A1/en active Pending
- 2021-03-17 WO PCT/EP2021/056803 patent/WO2021185897A1/en not_active Ceased
- 2021-03-17 EP EP21712999.8A patent/EP4121061A1/en active Pending
- 2021-03-17 BR BR112022015826A patent/BR112022015826A2/pt unknown
- 2021-03-17 CA CA3174699A patent/CA3174699A1/en active Pending
- 2021-03-17 AU AU2021238639A patent/AU2021238639B2/en active Active
- 2021-03-17 BR BR112022016241A patent/BR112022016241A2/pt unknown
- 2021-03-17 CN CN202180022225.5A patent/CN115315264A/zh active Pending
- 2021-03-17 WO PCT/EP2021/056788 patent/WO2021185890A1/en not_active Ceased
- 2021-03-17 CA CA3174698A patent/CA3174698A1/en active Pending
- 2021-03-17 CN CN202180022249.0A patent/CN115315266A/zh active Pending
- 2021-03-17 US US17/905,868 patent/US20230129389A1/en active Pending
- 2021-03-17 EP EP21713906.2A patent/EP4121076A1/en active Pending
- 2021-03-17 JP JP2022555990A patent/JP7808042B2/ja active Active
- 2021-03-17 AU AU2021238643A patent/AU2021238643A1/en active Pending
- 2021-03-17 JP JP2022556000A patent/JP7850670B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150306119A1 (en) | 2009-05-04 | 2015-10-29 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
| US20160339070A1 (en) | 2013-11-04 | 2016-11-24 | Wen Luan Wendy Hsiao | Use of herbal saponins to regulate gut microflora |
| CN109432304A (zh) | 2018-12-03 | 2019-03-08 | 杭州胡庆余堂药业有限公司 | 一种含铁皮石斛组合物在药物制备中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| C.-Z. Wang et al.,"Role of intestinal microbiome in American ginseng-mediated colon cancer protection in high fat diet-fed AOM/DSS mice",Clinical and Translational Oncology,2018年,Vol.20,p.302-312,DOI: 10.1007/s12094-017-1717-z |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021238639B2 (en) | 2026-06-25 |
| EP4121061A1 (en) | 2023-01-25 |
| WO2021185897A1 (en) | 2021-09-23 |
| US20230129389A1 (en) | 2023-04-27 |
| AU2021238643A1 (en) | 2022-10-20 |
| WO2021185890A1 (en) | 2021-09-23 |
| US20230124503A1 (en) | 2023-04-20 |
| BR112022015826A2 (pt) | 2022-10-04 |
| CA3174699A1 (en) | 2021-09-23 |
| CN115315264A (zh) | 2022-11-08 |
| CA3174698A1 (en) | 2021-09-23 |
| EP4121076A1 (en) | 2023-01-25 |
| BR112022016241A2 (pt) | 2022-10-11 |
| JP7850670B2 (ja) | 2026-04-23 |
| JP2023518064A (ja) | 2023-04-27 |
| JP2023519189A (ja) | 2023-05-10 |
| CN115315266A (zh) | 2022-11-08 |
| AU2021238639A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation | |
| US20230124503A1 (en) | Ginsenoside compositions | |
| Liu et al. | Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis | |
| Lu et al. | Pomegranate peel extract ameliorates the severity of experimental autoimmune encephalomyelitis via modulation of gut microbiota | |
| Wang et al. | Bifidobacteria exert species-specific effects on constipation in BALB/c mice | |
| Matsumoto et al. | Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis | |
| Chen et al. | Dietary saponins from four popular herbal tea exert prebiotic-like effects on gut microbiota in C57BL/6 mice | |
| Martirosyan et al. | The bioactive compounds of probiotic foods/supplements and their application in managing mental disorders | |
| JP2022518261A (ja) | プレバイオティクス剤として使用するための酵母製品およびそれを含む組成物 | |
| JP7514926B2 (ja) | 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用 | |
| Lan et al. | Protective mechanisms of Hovenia dulcis Thunb extracts on acute alcoholism and liver injury | |
| Butts et al. | Goat and cow milk differ in altering microbiota composition and fermentation products in rats with gut dysbiosis induced by amoxicillin | |
| Yang et al. | The regulatory effects of Lonicera japonica flos on fecal microbiota from humans with type 2 diabetes in a SHIME model | |
| Yi et al. | Intake of high-purity dietary fiber from Okara to prevent intestinal damage caused by acute ulcerative colitis | |
| Li et al. | Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora | |
| TW202444337A (zh) | 合生元組合物、代謝物及其預防及治療肥胖相關疾病的用途 | |
| CN117482138A (zh) | 芪胶升白胶囊在制备调节肠道微生物菌群紊乱的药物中的应用 | |
| TWI810645B (zh) | 乳桿菌組合物及其改善抗生素造成之焦慮症的用途 | |
| CN112956689A (zh) | 一种改善便秘的奇异果益生菌的组合物及其应用 | |
| Long et al. | Sishen Pill treats spleen-kidney yang deficiency IBS-D by influencing ATPase activity and intestinal microbiota | |
| JP7500897B2 (ja) | 腸内菌叢改善用組成物 | |
| Chi | Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis | |
| CN121081559A (zh) | 西红花、小蓟、桔红、黄芥子、黑芝麻和青果在制备益生元模拟物的药物或者制剂中的应用 | |
| JP2024018368A (ja) | 腸内細菌叢改善用組成物 | |
| CN110613802A (zh) | 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240314 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240318 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7808042 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |